Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | PGK1 | P00558 | 3/20 | 0.37 |
| ▸ | PGK2 | P07205 | 3/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11605816 | 0.85 | CYP2D6 (0.47) | CYP2D6SLC6A3CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL9016042 | 0.85 | CYP2D6 (0.41) | CYP2D6SLC6A3CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL1155059 | 0.81 | MEN1 (0.47) | CYP2D6SLC6A3CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL27994438 | 0.81 | CYP2D6 (0.39) | CYP2D6SLC6A3CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL11604146 | 0.79 | CYP3A4 (0.44) | CYP2D6SLC6A3CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL4083168 | 0.79 | IDO1 (0.37) | CYP2D6SLC6A3CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL15050442 | 0.78 | CYP3A4 (0.47) | CYP2D6SLC6A3CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL15051228 | 0.78 | CYP3A4 (0.47) | CYP2D6SLC6A3CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL15050445 | 0.78 | CYP3A4 (0.47) | CYP2D6SLC6A3CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL7108194 | 0.78 | SLC6A3 (0.40) | CYP2D6SLC6A3CYP3A4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| EP-2170890-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2011-10-26 | — | — | EP | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| EP-2170890-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009016516-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | TOMM34, TOMM70, TOMM40 | CYP2D6 2264/4885SLC6A3 3718/4885CYP3A4 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.